GlassScriptPhysician profile
Alan Kimura
NPI 1851343214
$545,821.72
in general payments reported to CMS, 2019-2025
24 companies · $8,140 in 2025
The $8,140 reported for 2025 was more than what 90% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $55K · 2021: $360K · 2022: $11K · 2023: $7,544 · 2024: $41K · 2025: $8,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Travel and Lodging: $7,069 · Food and Beverage: $2,134 · Entertainment: $20.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,730.00 |
| Travel and Lodging | $7,068.50 |
| Food and Beverage | $2,133.75 |
| Entertainment | $20.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $459,844.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $55,625.11 | 2023-2025 | |
| Spark Therapeutics, INC. | $21,824.42 | 2019-2021 | |
| Biogen, INC. | $4,127.88 | 2022-2024 | Byooviz |
| Allergan, INC. | $953.39 | 2019-2021 | |
| Genentech USA, INC. | $828.64 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $549.21 | 2019-2023 | Eylea, Eylea Hd |
| Genentech, INC. | $519.69 | 2019-2021 | |
| Coherus Oncology, INC. | $231.29 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $203.21 | 2019-2020 | |
| Janssen Global Services, LLC | $165.43 | 2022-2023 | |
| Apellis Pharmaceuticals, INC. | $164.58 | 2023 | Syfovre |
| Eyepoint US, INC. | $149.09 | 2019-2022 | |
| Notal Vision, INC. | $112.15 | 2021 | |
| Optos, INC. | $107.13 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $87.18 | 2022-2024 | Visudyne, Retisert, Xipere |
| Alimera Sciences, INC. | $82.18 | 2023-2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.00 | 2020 | |
| Astellas Pharma US INC | $71.47 | 2023 | |
| Rhythm Pharmaceuticals, INC. | $23.64 | 2021 | |
| Abbvie INC. | $22.71 | 2024 | |
| Alcon Vision LLC | $20.46 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Topcon Healthcare Solutions, INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,602,923.83 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kimura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.